Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies

NCT04450069 is registered in ClinicalTrials.gov with Calibr, a division of Scripps Research as lead sponsor.

NCT NCT04450069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Lead sponsor
Calibr, a division of Scripps Research
Phase
Phase 1
Overall status
Completed
Start date
August 14, 2020
Completion date
May 6, 2024
Enrollment
18 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, chronic lymphocytic leukemia (cll), diffuse large b cell lymphoma (dlbcl), follicular lymphoma (fl), lymphoplasmacytic lymphoma, mantle cell lymphoma, marginal zone lymphoma (mzl), primary mediastinal large b cell lymphoma, relapsed/refractory b-cell lymphomas, small lymphocytic lymphoma (sll), transformed follicular lymphoma, waldenstrom macroglobulinemia